- Home
- WINA vs PHVS Comparison
WINA vs PHVS Comparison
Compare WINA & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINA
- PHVS
- Stock Information
- Founded
- WINA 1988
- PHVS 2015
- Country
- WINA United States
- PHVS Switzerland
- Employees
- WINA N/A
- PHVS N/A
- Industry
- WINA Other Specialty Stores
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- WINA Consumer Discretionary
- PHVS Health Care
- Exchange
- WINA Nasdaq
- PHVS Nasdaq
- Market Cap
- WINA 1.4B
- PHVS 1.6B
- IPO Year
- WINA 1993
- PHVS 2021
- Fundamental
- Price
- WINA $403.17
- PHVS $22.22
- Analyst Decision
- WINA
- PHVS Buy
- Analyst Count
- WINA 0
- PHVS 6
- Target Price
- WINA N/A
- PHVS $36.50
- AVG Volume (30 Days)
- WINA 77.9K
- PHVS 217.3K
- Earning Date
- WINA 10-15-2025
- PHVS 11-12-2025
- Dividend Yield
- WINA 2.81%
- PHVS N/A
- EPS Growth
- WINA 2.56
- PHVS N/A
- EPS
- WINA 11.21
- PHVS N/A
- Revenue
- WINA $84,517,400.00
- PHVS N/A
- Revenue This Year
- WINA $7.05
- PHVS N/A
- Revenue Next Year
- WINA $3.60
- PHVS N/A
- P/E Ratio
- WINA $35.96
- PHVS N/A
- Revenue Growth
- WINA 3.35
- PHVS N/A
- 52 Week Low
- WINA $295.79
- PHVS $11.51
- 52 Week High
- WINA $527.37
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- WINA 35.46
- PHVS 45.81
- Support Level
- WINA $383.24
- PHVS $21.99
- Resistance Level
- WINA $435.62
- PHVS $23.64
- Average True Range (ATR)
- WINA 18.71
- PHVS 1.18
- MACD
- WINA -3.74
- PHVS -0.03
- Stochastic Oscillator
- WINA 24.67
- PHVS 45.38
About WINA Winmark Corporation
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.